Investing
GSK to boost respiratory portfolio with $1.4 billion Aiolos Bio deal
© Reuters. FILE PHOTO: GSK (GlaxoSmithKline) logo is seen in this illustration, August 10, 2022. REUTERS/Dado Ruvic/Illustration/File Photo
(Reuters) – British drugmaker GSK on Tuesday said it would acquire Aiolos Bio for a $1 billion upfront payment and up to $400 million in certain success-based regulatory milestone payments.
The acquisition will help beef up GSK’s respiratory diseases portfolio, which is currently growing on the back of its respiratory syncytial virus (RSV) vaccine’s strong launch.
Founded in 2023, Aiolos is developing a drug ready to enter late stage trials for the treatment of adult patients with asthma.
Read the full article here
-
Side Hustles7 days ago
3 Steps You Can’t Miss When Growing Your Business
-
Investing7 days ago
How I Transformed My Business by Letting Go of Low-Value Tasks
-
Make Money7 days ago
Here’s the Typical American’s Income at Every Age. How Do You Compare?
-
Investing7 days ago
Germany stocks lower at close of trade; DAX down 0.65% By Investing.com
-
Side Hustles5 days ago
How Your Body Language Can Help Win a Disagreement
-
Passive Income5 days ago
Are You Running Your Business, or Is Your Business Running You?
-
Investing5 days ago
7 Marketing Strategies to Help Your Startup Grow and Scale
-
Side Hustles6 days ago
How to Develop Empowered Leaders Within Your Own Team